Drug Trial Radar · NCT07675629
Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Aug 31, 2028
Study completion Aug 2029
Sponsor
- Lead sponsor
- Worcester HIV VaccineIndustry
- Sponsor type
- Industry
- Collaborators
- Desmond Tutu Health Foundation; Brigham and Women's Hospital
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA prime and gp120 (A,B,C,A/E) protein HIV-1 vaccines boost (PDPHV) with either Alhydrogel or GLA-SE in healthy, HIV-uninfected adults. Volunteers will receive either the PDPHV or the placebo (normal saline) by intramuscular injections. Some volunteers will receive Alhydrogel and others will receive GLA-SE as part of the protein boost.
Conditions
- HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))Biological
The polyvalent DNA Vaccines contains equal amounts of 5 individual DNA plasmid components utilizing the same vector pSW3891. Four plasmids each containing a codon optimized gp120 gene sequence from HIV-1 subtype A, B, C and CRF01\_AE consensus, and a fifth plasmid containing a codon optimized gag gene from subtype C.
PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))Biological
The Recombinant Protein Vaccines (gp120 (A, B, C, A/E)) contains equal amounts of 4 gp120 proteins.
Alhydrogel adjuvantBiological
PDPHV protein vaccines adjuvant
GLA-SE adjuvantBiological
PDPHV protein vaccines adjuvant
Placebo for DNA Vaccines, Protein Vaccines and AdjuvantsBiological
Sodium Chloride for Injection, USP 0.9%.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of local injection site (including DTH) reactogenicity signs and symptomsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
- Frequency of systemic reactogenicity signs and symptomsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
- Frequency of adverse events (AEs)Time frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
- Severity of local injection site (including DTH) reactogenicity signs and symptomsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
- Severity of systemic reactogenicity signs and symptomsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
- Severity of adverse events (AEs)Time frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
- Number of participants with early discontinuation of vaccinationsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
- Magnitude of serum HIV-1 Env-specific IgG responsesTime frame: Measured at 2 weeks after the last vaccination at month 6.5
- Breadth of gp70-V1V2 IgG and gp120 IgATime frame: Measured at 2 weeks after the last vaccination at month 6.5
- ADCC activitiesTime frame: Measured at 2 weeks after the last vaccination at month 6.5
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts
Emavundleni Clinical Research Site, Desmond Tutu Health Foundation
Cape Town, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.